Cargando…
Intravenous immunoglobulin as a therapeutic option for patients with worsening COVID-19 under rituximab
Severe cases of the new COVID-19 are being reported in immunosuppressed patients. The risk seems to depend on the type of immunosuppressive agents used and it is particularly important in patients under the long-lasting effect of rituximab. Information regarding the best therapeutic approach to thes...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240564/ https://www.ncbi.nlm.nih.gov/pubmed/34183316 http://dx.doi.org/10.1136/bcr-2021-243338 |